Expert Interview
A Second View: Discussing the recent FDA approval of Heron Therapeutics' Aponvie (aprepitant) - NK1 inhibitor IV infusion - and how if fits into the treatment landscape of Postoperative nausea and vomiting (PONV)
Ticker(s): HRTXInstitution: Private Practice
- Clinical Anesthesiology at Private Practice
- Manages 15 patients monthly with breakthrough postoperative nausea and vomiting and has prescribed the 40 mg oral dose of Aponvie preoperatively
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
